COVID19 - competitive landscape, page-198

I am feeling quite happy with the potential gains from a good HIV result, and I feel that the immune calming on the Covid front will place us in a good position all by itself. I have been looking over our competition and we appear to be way out in front for proven safety and pretty much the only one with a direct immune calming effect. Gotta love that!
I do appreciate that mob making progress on autophagy. If I had access to the Korean market I would send them some $ just for the health-span market possibilities. However, I don't see them as a direct competitor to BIT225 when proven, more like a useful adjunct.
You are right though. The safety results of long term dosing from so many human trials for HIV has to be placing us in a very nice position for any half decent results coming out of the Phase 2 Covid trial. Massive foot in the door, IMO.